Table 2. Correlations between clinicopathologic factors and FGFR2/SPRY2.
Characters | FGFR2 | P* | SPRY2 | P* | ||
---|---|---|---|---|---|---|
Low | High | Low | High | |||
Gender | ||||||
Male | 41 | 25 | 0.833 | 44 | 22 | 1.00 |
Female | 25 | 13 | 26 | 12 | ||
Age | ||||||
< 60 | 13 | 9 | 0.628 | 17 | 5 | 0.314 |
≥ 60 | 53 | 29 | 53 | 29 | ||
Tumor diameter (cm) | ||||||
≤ 5 | 19 | 12 | 0.825 | 20 | 11 | 0.820 |
> 5 | 47 | 26 | 50 | 12 | ||
Differentiation | ||||||
Well + Moderate | 38 | 21 | 0.840 | 41 | 18 | 0.674 |
Poor | 28 | 17 | 29 | 16 | ||
Tumor invasion | ||||||
T1 + T2 | 25 | 10 | 0.284 | 16 | 19 | 0.002 |
T3 + T4 | 41 | 28 | 54 | 15 | ||
Lymph node metastasis | ||||||
No (N0) | 34 | 9 | 0.007 | 21 | 22 | 0.001 |
Yes (N1/2/3) | 32 | 29 | 49 | 12 | ||
Distant metastasis | ||||||
M0 | 63 | 34 | 0.256 | 63 | 34 | 0.093 |
M1 | 3 | 4 | 7 | 0 | ||
TNM stage | ||||||
I | 8 | 4 | 0.701 | 7 | 5 | 0.217 |
II | 17 | 14 | 17 | 14 | ||
III | 32 | 14 | 39 | 13 | ||
IV | 6 | 3 | 7 | 2 | ||
Lauren subtype | ||||||
Intestinal | 43 | 15 | 0.031 | 35 | 23 | 0.096 |
Diffuse | 16 | 18 | 24 | 10 | ||
Mixed | 7 | 5 | 11 | 1 | ||
Peritoneal dissemination | ||||||
Yes | 64 | 38 | 0.532# | 68 | 34 | 1.00# |
No | 2 | 0 | 2 | 0 | ||
SPRY1 | ||||||
low | 54 | 34 | 0.401 | 61 | 27 | 0.386 |
high | 12 | 4 | 9 | 7 | ||
SPRY2 | ||||||
low | 39 | 31 | 0.029 | |||
high | 27 | 7 | ||||
SPRY3 | ||||||
low | 63 | 36 | 1.00# | 66 | 33 | 1.00# |
high | 3 | 2 | 4 | 1 | ||
SPRY4 | ||||||
low | 51 | 32 | 0.456 | 56 | 27 | 1.00 |
high | 15 | 6 | 14 | 7 | ||
FGFR2 | ||||||
low | 39 | 27 | 0.029 | |||
high | 31 | 7 |
means calculated by Chi-square test; #means calculated by Fisher test.
Abbreviations: FGFR2 = fibroblast growth factor receptor 2, SPRY = sprouty.